News

Both studies met their primary endpoints of non-inferiority to Gilead’s Viread® (tenofovir disoproxil fumarate, TDF) 300 mg based on the percentage of patients with HBV DNA levels below

A Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of ganaxolone IV is expected to initiate in the first half of 2016. Marinus Pharmaceuticals CEO Christopher

The recommendations were based on the review of data from 25 clinical studies undertaken in 15 different endemic and non-endemic countries across the world. More than 40,000 volunteers

Under the recommendation, Translarna would be made available as part of a confidential financial agreement between NHS England and PTC. The regulator noted that PTC should an acceptable

Gilotrif was initially approved in the US in July 2013 to treat epidermal growth factor receptor (EGFR)-positive metastatic non-small cell lung cancer (NSCLC). It has now been approved

Under the agreement, TGI would be Quark’s preferred provider of gene expression profiling services related to their clinical trial. The primary objective of the Quark/TGI collaboration will be

In this study, ZEPATIER demonstrated superiority on efficacy and safety endpoints compared to sofosbuvir plus pegIFN/RBV, based on pre-specified analyses. In the full analysis set (FAS) (n=255), the

ExxPharma will be responsible for technical development while Halo will have overall responsibility of drug product manufacturing and quality control at Halo’s state-of-the art GMP-compliant manufacturing facility in

The agreement provides Takeda access to Presage’s proprietary CIVO technology platform to enable identification of novel oncology drug combinations in solid tumors. Under the agreement, Presage and Takeda